Amrutanjan Health Care LimitedAMRUTANJANCorporate

Pharmaceuticals - Indian - Formulations Latest results: Mar 2026 5 quarters of data

₹513.80

MCap ₹1,485 Cr

Amrutanjan Health Care Limited — Stock analysis & AI research Amrutanjan Health Care Limited — Multibagger AI analysis Amrutanjan Health Care Limited — Seasonality — best & worst months Amrutanjan Health Care Limited — Technical setup — score, trend, support & resistance Amrutanjan Health Care Limited — Live exchange announcements

📈 MACD Bullish Crossover 📈 Bollinger Squeeze Stocks 📈 Stocks Above Anchored VWAP 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹150 Cr

Sales · Mar 2026

+10.6% YoY

₹26 Cr

Operating Profit · Mar 2026

17.1%

OPM % · Mar 2026

₹16 Cr

Net Profit · Mar 2026

₹5.60

EPS · Mar 2026

📝 Amrutanjan Health Care Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Amrutanjan Health Care Limited reported revenue of ₹150 crore for the quarter ended March 2026 (Q4 FY26), up 10.6% from ₹135 crore in the same quarter last year, and up 6.2% sequentially over the December 2025 quarter.

Net profit stood at ₹16 crore. Earnings per share (EPS) came in at ₹5.60.

Operating profit stood at ₹26 crore — an operating margin (OPM) of 17.1%.

Full year and trailing twelve months

For the full year FY25, Amrutanjan Health Care Limited posted revenue of ₹368 crore.

Valuation snapshot

At the current price of ₹513.80, AMRUTANJAN has a market capitalisation of ₹1,485 crore.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 10th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 46.52%, foreign institutional investors (FIIs) 3.47%, domestic institutional investors (DIIs) 6.90%, public shareholders 43.08% of Amrutanjan Health Care Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹1,485 Cr

Current Price ?

₹513.8

P/E ?

N/A

Industry P/E ?

21.30

P/B ?

4.01

P/S ?

N/A

P/FCF ?

-78.15

Enterprise Value ?

₹1,487 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.90%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

25.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹150 Cr

PAT — latest qtr ?

₹16 Cr

YoY qtr sales growth ?

10.6%

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

11%

Sales growth (5y) ?

12%

Profit growth (3y) ?

27%

Profit growth (5y) ?

15%

Financial Health

Debt ?

₹2 Cr

Debt to Equity ?

0.01

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

46.52%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-4.5%

Return 6 months ?

-6.1%

🗓️ Quarterly results (5 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2024	Dec 2024	Mar 2025	Dec 2025	Mar 2026	YoY %	QoQ %
Sales	110	123	135	141	150	+10.6%	+6.2%
Operating Profit	—	—	—	24	26	—	+8.1%
Other Income	—	—	—	3	5	—	+70.4%
Interest	0	0	0	0	0	+6.0%	-4.2%
Depreciation	—	—	—	—	2	—	—
Profit Before Tax	16	26	21	26	21	+0.8%	-20.3%
Net Profit	—	—	—	—	16	—	—
EPS	—	—	—	—	5.60	—	—
OPM %	—	—	—	16.8%	17.1%	—	+1.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY25	TTM	YoY %
Sales	—	₹368 Cr	—	—
Operating Profit	—	—	—	—
OPM %	—	—	—	—
NPM %	—	—	—	—
Other Income	—	—	—	—
Depreciation	—	—	—	—
Interest	—	₹0 Cr	—	—
EBIT	—	—	—	—
PBT	—	₹63 Cr	—	—
Tax	—	—	—	—
Net Profit	—	—	—	—
EPS	—	—	—	—
Material Cost	—	—	—	—
Employee Cost	—	—	—	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	3	3	3	3	+0.0%
Reserves	288	286	324	367	+13.3%
Borrowings	1	2	2	2	+0.0%
Other Liabilities	70	77	93	137	+47.3%
Total Liabilities	362	367	421	509	+20.9%
Fixed Assets	49	50	49	51	+4.1%
CWIP	1	2	16	105	+556.2%
Investments	5	0	0	3	—
Other Assets	307	315	356	349	-2.0%
Total Assets	362	367	421	509	+20.9%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	20	28	51	36	-29.4%
Cash from Investing Activity	-2	19	-31	-21	+32.3%
Cash from Financing Activity	-15	-48	-13	-14	-7.7%
Net Cash Flow	3	-1	6	1	-83.3%
Free Cash Flow	11	21	15	-19	-226.7%
CFO/OP	81%	86%	118%	73%	-38.1%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	32	42	45	44	-2.2%
Inventory Days	58	50	45	56	+24.4%
Days Payable	95	96	113	106	-6.2%
Cash Conversion Cycle	-6	-5	-23	-6	+73.9%
Working Capital Days	117	173	99	96	-3.0%
ROCE %	19%	21%	22%	25%	+13.6%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	46.52%	46.52%	46.52%	46.52%	46.52%	+0.0%
FIIs	2.41%	2.38%	2.27%	2.17%	3.47%	+59.9%
DIIs	12.70%	12.90%	13.00%	12.66%	6.90%	-45.5%
Public	38.34%	38.16%	38.18%	38.61%	43.08%	+11.6%
Others	0.04%	0.04%	0.04%	0.04%	—	—
No. of Shareholders	49,431	47,954	46,675	45,805	46,186	+0.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SHILPAMED Shilpa Medicare	₹1,032.00	20,184	67.5	1,683	297	28.4%	17.7%	47.7%	454.9%	44.9%	115.2%
2	MARKSANS Marksans Pharma	₹332.50	15,068	29.1	3,171	521	22.5%	16.4%	12.5%	9.7%	35.6%	174.8%
3	BLISSGVS Bliss GVS	₹680.50	7,236	52.9	1,005	142	19.7%	14.1%	14.4%	48.7%	37.6%	15.8%
4	JSLL Jeena Sikho	₹507.55	6,309	26.7	852	236	42.6%	27.7%	17.1%	85.5%	28.8%	28.0%
5	SENORES Senores Pharmaceuticals	₹1,327.50	6,114	46.6	692	131	29.5%	19.0%	63.0%	108.7%	30.6%	43.8%
6	WINDLAS Windlas Biotech	₹1,129.50	2,331	35.7	942	66	11.1%	7.1%	18.9%	9.0%	18.1%	-0.1%
7	VENUSREM Venus Remedies	₹1,651.10	2,210	19.0	811	117	20.4%	14.4%	17.9%	127.9%	35.6%	139.3%
8	SYNCOMF Syncom Formulations	₹23.44	2,203	1.3	12,547	1,729	15.2%	13.8%	2566.9%	3386.8%	7.4%	57.7%
9	HESTERBIO Hester Biosciences	₹2,187.90	1,861	13.6	318	137	30.8%	43.0%	4.7%	101.2%	-8.4%	460.8%
10	AMRUTANJAN Amrutanjan Health	₹489.00	1,413	26.2	512	54	14.4%	10.5%	11.0%	1.3%	9.5%	-45.4%
11	LINCOLN Lincoln Pharmaceuticals	₹601.50	1,205	12.5	694	97	14.6%	14.0%	7.6%	7.2%	15.1%	30.9%
12	BAFNAPH Bafna Pharmaceuticals	₹301.45	713	91.6	143	8	8.2%	5.5%	3.3%	166.8%	-23.2%	-97.8%
13	KILITCH Kilitch Drugs	₹198.00	692	16.1	237	29	15.3%	12.3%	18.7%	20.1%	4.0%	-13.0%
14	MEDICAMEQ Medicamen Biotech	₹323.80	439	1.3	9,516	381	10.1%	4.0%	5751.8%	3308.0%	11.3%	15.3%
15	QUESTLAB Quest Laboratories	₹137.50	225	13.7	150	16	12.7%	11.0%	25.8%	34.9%	-30.2%	47.9%
16	JFLLIFE Jfl Life	₹51.05	168	24.7	131	7	9.1%	5.2%	60.2%	53.1%	-4.2%	48.5%
17	ZENITHDRUG Zenith	₹78.45	135	41.7	171	4	7.0%	2.3%	—	—	40.9%	100.0%
18	ALPA Alpa Laboratories	₹62.32	131	29.6	111	4	1.7%	4.0%	-5.9%	-22.5%	25.2%	-91.7%
19	MEDIORG Medicamen	₹101.45	119	—	22	-3	-12.9%	-14.0%	—	—	-77.5%	-383.0%
20	BIOFILCHEM Biofil Chemicals	₹33.13	54	110.4	34	0	2.3%	1.4%	-15.0%	405.5%	92.1%	-95.5%

❓ Frequently asked questions

What was Amrutanjan Health Care Limited's revenue in Q4 FY26?

What was Amrutanjan Health Care Limited's net profit in Q4 FY26?